| Year |
Citation |
Score |
| 2024 |
Colucci M, Zumerle S, Bressan S, Gianfanti F, Troiani M, Valdata A, D'Ambrosio M, Pasquini E, Varesi A, Cogo F, Mosole S, Dongilli C, Desbats MA, Contu L, Revankdar A, ... ... Alimonti A, et al. Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer Cell. PMID 38428412 DOI: 10.1016/j.ccell.2024.02.004 |
0.412 |
|
| 2023 |
Alimonti A. Overcoming immune evasion in advanced prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 21: 533-535. PMID 37948589 |
0.394 |
|
| 2023 |
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, ... ... Alimonti A, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. PMID 37844613 DOI: 10.1038/s41586-023-06696-z |
0.374 |
|
| 2023 |
Guccini I, Tang G, To TT, Di Rito L, Le Blanc S, Strobel O, D'Ambrosio M, Pasquini E, Bolis M, Silva P, Kabakci HA, Godbersen S, Alimonti A, Schwank G, Stoffel M. Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. Iscience. 26: 107368. PMID 37559908 DOI: 10.1016/j.isci.2023.107368 |
0.304 |
|
| 2023 |
Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, de Bono J, Alimonti A. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nature Reviews. Urology. PMID 37491512 DOI: 10.1038/s41585-023-00795-2 |
0.42 |
|
| 2023 |
Troiani M, Colucci M, D'Ambrosio M, Guccini I, Pasquini E, Varesi A, Valdata A, Mosole S, Revandkar A, Attanasio G, Rinaldi A, Rinaldi A, Bolis M, Cippà P, Alimonti A. Author Correction: Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nature Communications. 14: 4386. PMID 37474528 DOI: 10.1038/s41467-023-40080-9 |
0.301 |
|
| 2023 |
Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D'Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, ... ... Alimonti A, et al. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature Cancer. PMID 37460872 DOI: 10.1038/s43018-023-00594-z |
0.5 |
|
| 2023 |
Alvarez-Arzola R, Bancaro N, Lai P, Attanasio G, Pellegrini L, Troiani M, Colucci M, Mosole S, Pasquini E, Alimonti A, Mesa C. VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer. Cell Communication and Signaling : Ccs. 21: 76. PMID 37055829 DOI: 10.1186/s12964-023-01095-3 |
0.426 |
|
| 2023 |
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, de la Maza MDF, Rescigno P, ... ... Alimonti A, et al. Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]. European Urology. PMID 36964041 DOI: 10.1016/j.eururo.2023.03.005 |
0.371 |
|
| 2023 |
Bancaro N, Calì B, Troiani M, Elia AR, Arzola RA, Attanasio G, Lai P, Crespo M, Gurel B, Pereira R, Guo C, Mosole S, Brina D, D'Ambrosio M, Pasquini E, ... ... Alimonti A, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell. 41: 602-619.e11. PMID 36868226 DOI: 10.1016/j.ccell.2023.02.004 |
0.422 |
|
| 2022 |
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, ... ... Alimonti A, et al. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology. PMID 36114082 DOI: 10.1016/j.eururo.2022.09.004 |
0.338 |
|
| 2022 |
Troiani M, Colucci M, D'Ambrosio M, Guccini I, Pasquini E, Varesi A, Valdata A, Mosole S, Revandkar A, Attanasio G, Rinaldi A, Rinaldi A, Bolis M, Cippà P, Alimonti A. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nature Communications. 13: 2177. PMID 35449130 DOI: 10.1038/s41467-022-29824-1 |
0.311 |
|
| 2021 |
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, ... ... Alimonti A, et al. HER3 is an Actionable Target in Advanced Prostate Cancer. Cancer Research. PMID 34753775 DOI: 10.1158/0008-5472.CAN-21-3360 |
0.384 |
|
| 2021 |
Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, Attanasio G, Troisi J, Minini M, Mosole S, Revandkar A, Pasquini E, Elia AR, Bossi D, Rinaldi A, ... ... Alimonti A, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science (New York, N.Y.). 374: 216-224. PMID 34618582 DOI: 10.1126/science.abf8403 |
0.392 |
|
| 2021 |
Paschalis A, Welti J, Neeb AJ, Yuan W, Figueiredo I, Pereira R, Ferreira A, Riisnaes R, Rodrigues DN, Jiménez-Vacas JM, Kim S, Uo T, Micco PD, Tumber A, Islam MS, ... ... Alimonti A, et al. JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research. 81: 1087-1100. PMID 33822745 DOI: 10.1158/0008-5472.CAN-20-1807 |
0.401 |
|
| 2021 |
Guo C, Crespo M, Gurel B, Dolling D, Rekowski J, Sharp A, Petremolo A, Sumanasuriya S, Rodrigues DN, Ferreira A, Pereira R, Figueiredo I, Mehra N, Lambros MBK, Neeb A, ... ... Alimonti A, et al. CD38 in Advanced Prostate Cancers. European Urology. PMID 33678520 DOI: 10.1016/j.eururo.2021.01.017 |
0.317 |
|
| 2021 |
Bernasocchi T, El Tekle G, Bolis M, Mutti A, Vallerga A, Brandt LP, Spriano F, Svinkina T, Zoma M, Ceserani V, Rinaldi A, Janouskova H, Bossi D, Cavalli M, Mosole S, ... ... Alimonti A, et al. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications. 12: 734. PMID 33531470 DOI: 10.1038/s41467-020-20820-x |
0.443 |
|
| 2020 |
Guccini I, Revandkar A, D'Ambrosio M, Colucci M, Pasquini E, Mosole S, Troiani M, Brina D, Sheibani-Tezerji R, Elia AR, Rinaldi A, Pernigoni N, Rüschoff JH, Dettwiler S, De Marzo AM, ... ... Alimonti A, et al. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. Cancer Cell. PMID 33186519 DOI: 10.1016/j.ccell.2020.10.012 |
0.472 |
|
| 2020 |
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Author Correction: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics. PMID 32820258 DOI: 10.1038/S41588-020-0688-0 |
0.381 |
|
| 2020 |
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. Prostate carcinogenesis: inflammatory storms. Nature Reviews. Cancer. PMID 32546840 DOI: 10.1038/S41568-020-0267-9 |
0.374 |
|
| 2020 |
Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, ... ... Alimonti A, et al. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. The Journal of Clinical Investigation. PMID 32250342 DOI: 10.1172/JCI131133 |
0.538 |
|
| 2019 |
Arreal L, Piva M, Fernández S, Revandkar A, Schaub-Clerigué A, Villanueva J, Zabala-Letona A, Pujana M, Astobiza I, Cortazar AR, Hermanova I, Bozal-Basterra L, Arruabarrena-Aristorena A, Crespo JR, Valcarcel-Jimenez L, ... ... Alimonti A, et al. Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Cell Death and Differentiation. PMID 31570853 DOI: 10.1038/s41418-019-0407-5 |
0.312 |
|
| 2019 |
Di Mitri D, Mirenda M, Vasilevska J, Calcinotto A, Delaleu N, Revandkar A, Gil V, Boysen G, Losa M, Mosole S, Pasquini E, D'Antuono R, Masetti M, Zagato E, Chiorino G, ... ... Alimonti A, et al. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. Cell Reports. 28: 2156-2168.e5. PMID 31433989 DOI: 10.1016/j.celrep.2019.07.068 |
0.351 |
|
| 2018 |
Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, ... ... Alimonti A, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of Clinical Investigation. 128: 5185. PMID 30382943 DOI: 10.1172/JCI125184 |
0.383 |
|
| 2018 |
Sgrignani J, Chen J, Alimonti A, Cavalli A. How phosphorylation influences E1 subunit pyruvate dehydrogenase: A computational study. Scientific Reports. 8: 14683. PMID 30279533 DOI: 10.1038/s41598-018-33048-z |
0.328 |
|
| 2018 |
Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, ... ... Alimonti A, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of Clinical Investigation. PMID 30179225 DOI: 10.1172/Jci121924 |
0.417 |
|
| 2018 |
Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, ... ... Alimonti A, et al. Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. PMID 30089860 DOI: 10.1038/s41588-018-0181-1 |
0.422 |
|
| 2018 |
Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, ... ... Alimonti A, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. PMID 29950727 DOI: 10.1038/s41586-018-0266-0 |
0.385 |
|
| 2018 |
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, ... ... Alimonti A, et al. Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. PMID 29342137 DOI: 10.1038/Nature25470 |
0.414 |
|
| 2018 |
Chen J, Guccini I, Mitri DD, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, ... ... Alimonti A, et al. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. PMID 29335542 DOI: 10.1038/s41588-017-0026-3 |
0.516 |
|
| 2017 |
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, ... ... Alimonti A, et al. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. PMID 28658205 DOI: 10.1038/Nature22964 |
0.418 |
|
| 2016 |
Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, ... ... Alimonti A, et al. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nature Communications. 7: 13719. PMID 27941799 DOI: 10.1038/Ncomms13719 |
0.504 |
|
| 2016 |
Matic I, Revandkar A, Chen J, Bisio A, Dall'Acqua S, Cocetta V, Brun P, Mancino G, Milanese M, Mattei M, Montopoli M, Alimonti A. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay. Aging. PMID 27922821 DOI: 10.18632/aging.101076 |
0.351 |
|
| 2016 |
Di Mitri D, Alimonti A. Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. Trends in Cell Biology. 26: 215-226. PMID 26564316 DOI: 10.1016/j.tcb.2015.10.005 |
0.306 |
|
| 2015 |
Di Mitri D, Toso A, Alimonti A. Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors. Oncoimmunology. 4: e988473. PMID 26405613 DOI: 10.4161/2162402X.2014.988473 |
0.323 |
|
| 2015 |
Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, ... ... Alimonti A, et al. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nature Communications. 6: 7227. PMID 26085373 DOI: 10.1038/ncomms8227 |
0.424 |
|
| 2015 |
Di Mitri D, Toso A, Alimonti A. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3108-12. PMID 25967145 DOI: 10.1158/1078-0432.CCR-14-2261 |
0.319 |
|
| 2015 |
Toso A, Di Mitri D, Alimonti A. Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity. Oncoimmunology. 4: e994380. PMID 25949917 DOI: 10.4161/2162402X.2014.994380 |
0.34 |
|
| 2014 |
Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, ... ... Alimonti A, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Reports. 9: 75-89. PMID 25263564 DOI: 10.1016/J.Celrep.2014.08.044 |
0.324 |
|
| 2011 |
Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Research. 71: 629-33. PMID 21266353 DOI: 10.1158/0008-5472.Can-10-2488 |
0.343 |
|
| 2010 |
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis Journal of Clinical Investigation. 120: 681-693. PMID 20197621 DOI: 10.1172/Jci40535 |
0.46 |
|
| 2009 |
Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Science Signaling. 2: ra44. PMID 19690330 DOI: 10.1126/Scisignal.2000053 |
0.314 |
|
| 2009 |
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics. 41: 619-24. PMID 19396168 DOI: 10.1038/Ng.370 |
0.439 |
|
| 2009 |
Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. ETS rearrangements and prostate cancer initiation. Nature. 457: E1; discussion E2-3. PMID 19212347 DOI: 10.1038/Nature07738 |
0.364 |
|
| 2009 |
Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Science Signaling. 2: ra2. PMID 19176516 DOI: 10.1126/Scisignal.2000189 |
0.422 |
|
| 2008 |
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Journal of Clinical Investigation. 118: 3065-3074. PMID 18725988 DOI: 10.1172/Jci34739 |
0.405 |
|
| 2008 |
Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes & Development. 22: 2172-7. PMID 18708577 DOI: 10.1101/Gad.1699608 |
0.459 |
|
| 2007 |
Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, et al. Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression Cell. 128: 141-156. PMID 17218261 DOI: 10.1016/J.Cell.2006.11.040 |
0.341 |
|
| 2007 |
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 128: 129-39. PMID 17218260 DOI: 10.1016/J.Cell.2006.11.039 |
0.355 |
|
| 2006 |
Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 441: 523-7. PMID 16680151 DOI: 10.1038/Nature04809 |
0.358 |
|
| Show low-probability matches. |